1 Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich general practitioner project. Diabetologia 1996;39:1540–5.
2 Haffner SMet al. Cardiovascular risk factors in confirmed prediabetic individuals. JAMA 1990;263:2893–8.
3 American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S13–28.
4 Haneda M, Noda M, Origasa H, et al. Japanese clinical practice guideline for diabetes 2016. Diabetol Int 2018;9:1–45.
5 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115–26.
6 Higashi Y, Noma K, Yoshizumi M, et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009;73:411–8.
7 Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002;40:505–10.
8 Gokce N, Keaney JF, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567–72.
9 Brevetti G, Silvestro A, Schiano V, et al. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to Ankle-brachial pressure index. Circulation 2003;108:2093–8.
10 Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363–8.
11 Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009;120:502–9.
12 Maruhashi T, Soga J, Fujimura N, et al. Relationship between flow- mediated vasodilation and cardiovascular risk factors in a large community-based study. Heart 2013;99:1837–42.
13 Henry RMA, Ferreira I, Kostense PJ, et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; the Hoorn study. Atherosclerosis 2004;174:49–56.
14 Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide- mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567–74.
15 Vehkavaara S, Seppälä-Lindroos A, Westerbacka J, et al. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 1999;22:2055–60.
16 Xiang G-da, Wang Y-lin. Regular aerobic exercise training improves endothelium-dependent arterial dilation in patients with impaired fasting glucose. Diabetes Care 2004;27:801–2.
17 Rodriguez CJ, Miyake Y, Grahame-Clarke C, et al. Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol 2005;96:1273–7.
18 Su Y, Liu X-M, Sun Y-M, et al. Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. Am J Cardiol 2008;102:497–8.
19 Tomiyama H, Kohro T, Higashi Y, et al. A multicenter study design to assess the clinical usefulness of semi-automatic measurement of flow-mediated vasodilatation of the brachial artery. Int Heart J 2012;53:170–5.
20 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486–97.
21 American diabetes association: clinical practice recommendations 1999. Diabetes Care 1999;22(Suppl 1):S1–114.
22 Maruhashi T, Soga J, Fujimura N, et al. Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler Thromb Vasc Biol 2013;33:1401–8.
23 Tomiyama H, Kohro T, Higashi Y, et al. Reliability of measurement of endothelial function across multiple institutions and establishment of reference values in Japanese. Atherosclerosis 2015;242:433–42.
24 Inoue T, Matsuoka H, Higashi Y, et al. Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens Res 2008;31:2105–13.
25 Diehl KJ, Templeton DL, Ma J, et al. Impaired fasting blood glucose is associated with increased endothelin-1 vasoconstrictor tone. Atherosclerosis 2013;229:130–3.
26 Genuth S, Alberti KGMM, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–7.
27 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–20.
28 Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000;97:12222–6.
29 Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859–66.
30 Kolm-Litty V, Sauer U, Nerlich A, et al. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 1998;101:160–9.
31 Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29:2064–71.
32 Aroor AR, McKarns S, Demarco VG, et al. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013;62:1543–52.
33 Supriya R, Tam BT, Yu AP, et al. Adipokines demonstrate the interacting influence of central obesity with other cardiometabolic risk factors of metabolic syndrome in Hong Kong Chinese adults. PLoS One 2018;13:e0201585.
34 Després J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881–7.
35 Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840–4.
36 Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata diabetes study. Diabetes Care 1999;22:920–4.
37 Doi Y, Ninomiya T, Hata J, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2010;41:203–9.
38 Shaye K, Amir T, Shlomo S, et al. Fasting glucose levels within the high normal range predict cardiovascular outcome. Am Heart J 2012;164:111–6.
39 Pereg D, Elis A, Neuman Y, et al. Cardiovascular risk in patients with fasting blood glucose levels within normal range. Am J Cardiol 2010;106:1602–5.
40 Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care 2013;36:1789–96.
41 Sasaki S, Higashi Y, Nakagawa K, et al. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am J Hypertens 2002;15:302–9.
42 Higashi Y, Sasaki S, Sasaki N, et al. Daily aerobic exercise improves reactive hyperemia in patients with essential hypertension. Hypertension 1999;33:591–7.
43 Goto C, Higashi Y, Kimura M, et al. Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation 2003;108:530–5.
44 Schreuder THA, Green DJ, Nyakayiru J, et al. Time-course of vascular adaptations during 8 weeks of exercise training in subjects with type 2 diabetes and middle-aged controls. Eur J Appl Physiol 2015;115:187–96.
45 Thijssen DHJ, Bruno RM, van Mil ACCM, et al. Expert consensus and evidence-based recommendations for the assessment of flow- mediated dilation in humans. Eur Heart J 2019;40:2534–47.
論文の公開元へ
